Category Archives: IBB

Monday’s Damage Assessment

October 13, 2025 By in $SPSIBI, Bert Dohmen, BIS, DRIP, DRV, DUST, DXD, FAZ, IBB, JDST, LABD, LABD-25-13, Positions, QID, SDS, SOXS, SPBIO, TZA, XBI

Where’s The Crash?

The YouTube weekend ‘consensus’ was for a Monday morning massacre.

So, where is it?

Bert Dohmen, said it best in this interview, (paraphrasing), ‘If everybody agrees with our analysis, then we have to get a new analysis’.

Monday’s First 15-Minutes

After the first 15-minutes of trade, an assessment was made on the ‘Leveraged Inverse Funds’.

The point being, since this site’s maintaining a short position in biotech (via LABD), how did it fare when compared to the other funds?

After the first 15-minutes of trade, the table at left shows all inverse funds being tracked, in the red, some painfully so (like SOXS, JDST, DUST).

All red, except for the two biotech’s, LABD and BIS.

Those two funds are short vehicles for biotech XBI and IBB, respectively.

The XBI index has not (yet) made a new daily low.

Conversely, the inverse fund LABD, has not made a new daily high.

With that said, the stop on LABD-25-13, remains at last Friday’s low of 33.17 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Markets Blow-Up … A Review

October 11, 2025 By in $SPSIBI, Bonds, CDNS, DIA, Dow 30, IBB, Natural Gas, SPBIO, TLT, UNG, WFC, Wyckoff, XBI

In The Aggregate

Whether or not we’re at the ‘anxiety’ point shown on the chart, is yet to be seen.

Markets are open this coming Monday, except for bonds, adding to the weekend angst.

Reviewing The (past) Week

Posts over last week, even the weeks before, showed from a Wyckoff perspective, something was about to happen.

Cadence Design … Reversal Ready, link here.

When The Bonds Spike, link here.

Wells Fargo Top … 86.66, link here.

Biotech (short) Set-Up, link here.

Top of The Dow, link here.

In retrospect and in aggregate, it’s now obvious something was amiss.

The ‘Art’ of Wyckoff

Wyckoff technique is more art than science, more intuitive than calculated, more ephemeral than certain.

We’ll get into what happens when logic overrides that art, in the next update; Nat-Gas UNG.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech (short) Set-Up

October 9, 2025 By in $SPSIBI, IBB, LABD, LABD-25-13, Positions, SPBIO, Up-Thrust, XBI 3 Comments

Breakout Into Resistance

Both biotech funds, IBB, and XBI, are now in an up-thrust (potential reversal) condition.

In each case, the ETFs have pushed through a long-established trading range, straight into resistance.

The last update focused on less liquid IBB, because it was not known if heavily traded XBI, would push through its trading range (being the weaker of the two).

Since that initial update, both indices are now above their trading range.

Of course, what happens next is the question.

Biotech XBI, Weekly

The blue line is long established resistance.

The black dashed line is the top of the trading range and the up-thrust condition.

At this point anything can happen.

XBI, could reverse immediately or grind its way along, dissipate momentum, or even move higher.

We’re at the point where the risk of being wrong on a short position is least (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech At The Edge

October 7, 2025 By in Biotech, BIS, BIS-25-01, IBB, Positions, Spring-to-Up-Thrust 1 Comment

Where The Risk Is Least

Biotech tracking fund IBB, has posted itself into an interesting position.

Last week, it launched higher over +7% and penetrated long established resistance; this week, it has essentially stopped dead.

Biotech IBB, Weekly

If what we have is the repeating pattern of ‘spring-to-up-thrust’, it’s happening on a massive scale.

For a short position, the broker being used indicates HTB (Hard To Borrow); there are potential fees associated with selling short.

With that said, the 2X leveraged Inverse fund is BIS. However, it too has problems. It’s not liquid; typically, 14K – 20K shares a day.

Nonetheless, short established via BIS (BIS-25-01) with stop at the week’s low of 11.95 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Bubble’ & The ‘Beast’

September 26, 2025 By in $SPSIBI, Artificial Intelligence, Biotech, BIS, IBB, Positions, Semiconductors, SOXS, SOXX, SOXX-25-14, SPBIO, Up-Thrust, Wyckoff, XBI 3 Comments

Downside For Both?

The ‘bubble’ is obvious, Artificial Intelligence.

The ‘beast’, not so much, but revealed below.

The last update, presented a case for the SOXX top, a proxy for A.I.

Note: If the SOXX, has made its final high, it’s still very early in the reversal:

Wyckoff said a century ago, ‘It’s as if the weight of a feather can move the market in either direction’.

That’s where we are now.

For biotech (IBB, XBI), different forces are at work.

Biotech IBB, Weekly

The 38.2%, retrace from 9/19 high, to 9/25 low, is in the vicinity of 140.90 (magenta dashed line).

Fridays are typically biased to the upside.

There’s a possibility IBB, may test (upward) throughout the session, heading to (at or near) 38%, by the end of the day (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Margin Debt … $1-Trillion

September 18, 2025 By in $SPSIBI, Biotech, DIA, IBB, IWM, IYR, LABD, LABD-25-11, Positions, QQQ, S&P, S&P 500, SPBIO, SPY, Up-Thrust, Wyckoff, XBI, XLF, ZeroHedge

When it Implodes

Is the bell ringing?

Is this it?

In the pre-market, SPY, DIA, XLF, QQQs, all-time highs.

Meanwhile, beneath the surface, it’s getting a bit ‘uncomfortable’.

One Trillion in margin debt as reported here and here.

The Ones To Watch

While all eyes are focused on the leaders (above), at least three markets are not participating:

Real Estate, IYR, Russell IWM, biotech, IBB, and XBI.

From a Wyckoff perspective, for short candidates, these are the ones to watch (not advice, not a recommendation).

Biotech, XBI

As stated in the prior update, XBI may have formed a triple top within and ‘up-thrust’, link here.

The obvious areas to watch for today’s session, are yesterday’s high and low.

A new high puts the up-thrust into question; new low, adds (a small) confirmation to reversal.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … The Big One?

September 10, 2025 By in $SPSIBI, Biotech, GDX, GDXJ, Gold & Silver, Gold Miners, Greg Hunter, HOOD, IBB, Karen Kingston, LABD, LABD-25-10, Nasdaq, ORCL, Positions, QQQ, S&P, S&P 500, SPBIO, Speck-Effect, SPY, The Speck, XBI 3 Comments

Next Leg Lower

Unfortunately, the (mad scientist) graphic at left, is not too far removed from what’s really going on in biotech.

While the S&P, Nasdaq Qs, Gold Miners, Semiconductors, Financials, The HOOD, ORCL, and others, continue to make all-time highs, conspicuously absent is biotech, XBI and IBB.

Now, it appears that quietly, in the background, XBI is reversing to the downside.

Biotech XBI, Daily Close

The up-thrust is there, but is a weak penetration of resistance.

Even so, on the ‘test’, volume contracted by -49.24%, when compared to volume on the upside penetration.

Until proven otherwise, this set-up appears to (currently) be the best short opportunity.

With that said, all other short positions have been closed to focus on biotech.

Leveraged inverse fund LABD is being used at this juncture: Trade LABD-25-10, with stop at the session low (not advice, not a reocmmendiaton).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Assessing The (market) Damage

April 5, 2025 By in Car Questions Answered, CVNA, DIA, IBB, IWM, IYM, IYR, KMX, QQQ, SOXX, SPBIO, SPY, XLF, XOP 1 Comment

Sifting Through The Rubble

There are sure to be plenty of post-mortems over the weekend; usual suspects giving us their assessment on what’s already happened. 🙂

Sometimes the question, is not ‘what’s happened’, but ‘what has not happened’.

That’s where the opportunity may lie.

Market Implosion

Over the past week, there were wide price bars, with action unstable in all major indices (ETFs): DIA, IBB, IWM, IYM, IYR, QQQ, SOXX, SPBIO, SPY, XLF, and XOP.

However, what did not implode (completely), are the car dealerships; specifically, CarMax and Carvana.

For this update, we’ll look at CarMax.

CarMax, KMX, Weekly Close

On a close basis, KMX, has bounced off the lower wedge boundary and is near the resistance area (magenta line).

Price action could be positively biased in the coming week as a result of ‘tax refund’ car buying (not advice, not a recommendation)

According to ‘Car Questions Answered‘, it’s a yearly ‘thing’.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Downside Leader … Biotech

January 14, 2025 By in $SPSIBI, Biotech, IBB, IWM, LABD-25-01, Russell 2000, SPBIO, TZA, TZA-25-01, Wyckoff, XBI, ZeroHedge Tags: , , , , 1 Comment

Confirming, Right-Side Channel

It’s a recurring theme with biotech.

Over and again, this sector (IBB, XBI) is not participating in tandem with the other major indices.

Today’s pre-market mayhem higher over supposed slower outlays of possible trade tariffs to happen some-time, some-day, caused the major indices to launch upward. 🙂

Well, everybody seemed to be blasting higher except one sector, biotech.

Wyckoff Directed Action

No matter what the ‘narrative’ may be, Wyckoff analysis directs us to look at what the market is actually doing, then interpret the action.

Early after the open, trade TZA-25-01, was exited, +8.9% gain, short position opened in biotech via LABD, Trade: LABD-25-01 (not advice, not a recommendation).

Biotech XBI, Daily

Today posted outside down, taking out both the high and low of the prior session.

Note the trading channel and width, Fibonacci 13-Days.

Also note the two ‘breakaway gaps’. The second one on January 10th, much wider than November 12th, last year.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Moderna Reversal

June 19, 2024 By in $SPSIBI, Biotech, Dr. John Campbell, Elliott Wave, IBB, Livermore, Loeb, MRNA, PFE, Prechter, SPBIO, Wyckoff, XBI, ZeroHedge 1 Comment

When Price Action Heads South …

Said many times;

‘When price action heads south, bad news comes out.’

That’s a slightly different take on Prechter’s (Elliott Wave) observation.

‘Price action leads the news; not the other way around’.

Going to BigCharts, typing in MRNA, shows they still have no P/E.

So, the ‘bad news’, can’t be they’re not making any money because they’re not doing it, now. 🙂

I wonder, who can it be now?

For a clue to the (potential) answer, we can look at what’s happening to Pfizer, link here and here.

However, let’s not get ourselves wrapped around the axle on events, forecast years ago.

Rather, let’s go straight to the truth, the price action and see what it’s telling us.

Moderna MRNA, Weekly

The entire move from low to highs is shown. Included on the chart, are two Fibonacci indicators.

One is the standard ‘retrace’ indicator; the other, is a ‘projection’ indicator.

The ‘projection’ is based off the ‘a-b-c’ move from the lows of November 2nd, 2023, to the highs on May 24, 2024.

The retrace and projections are hard to see, so the ‘Detail‘, arrow is where we’re headed next on the daily.

Moderna MRNA, Daily

If there ever was a chart to once-and-for-all, refute, dismiss, trash, the whole ‘Fundamentals’ argument, that earnings, interest rates or some other ‘Voodoo economics’, moves prices, this is it:

MRNA, price action hit the 23.6% retrace level (exactly) for two days before moving on to hit the 161.8%, projection (exactly) before reversing.

Note the ‘100%‘ level as well; price action confirmed this area (exactly) three times! Once on the way up and two times on the way down (third time, not shown).

A century ago, Livermore said, ‘It’s all about the numbers’.

Strategy, First

Just as Livermore was primary a strategist, so is this site’s method of analyzing the markets, i.e., Strategy, Tactics, Focus, in that order (not advice, not a recommendation).

The news has been replete with reports like this one and this one.

Another panic ahead?

Sounds like it but at least in the case of Moderna, the chart itself says (effectively):

‘There’s no money in it’.

That means, another wave like we saw several years ago, is not the most likely future event (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279